Phase 1 · NCT06313528
A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943
A Randomized, Double-Blind, Phase 1 Study to Investigate the Effect of LY3437943 Versus Placebo on Calorie Intake and Energy Expenditure in Participants With Obesity Under Calorie Restriction
What this means
The registry describes the study design and status. This label does not mean results have been reported.
Figure / record sourceLast verified 23 Oct 2026
Registry record
Trial details
- Trial
- A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943
- ClinicalTrials.gov ID
- NCT06313528
- Indication
- Obesity
- Phase
- Phase 1
- Study type
- Interventional
- Sponsor
- Eli Lilly and Company
- Enrolment
- 85
- Status
- Completed
- Interventions
- Drug: LY3437943; Other: Placebo
- Comparator
- Placebo
- Eligible ages
- 18 Years – 60 Years
- Locations
- 3 sites · United States
- Study start
- 20 Mar 2024
- Primary completion
- 26 Aug 2025
- Study completion
- 26 Aug 2025
Verification
- Last verified
- 23 Oct 2026
- Source
- ClinicalTrials.gov
- Registry last updated
- 23 Sept 2025
Endpoints
Primary
Change from Baseline in Total Calorie Intake at Lunch and Dinner (Combined)
Secondary
Change from Baseline in Sleep Metabolic Rate (SMR); Change from Baseline in SMR; Change from Baseline in 24-hour Energy Expenditure (EE); Change from Baseline in 24-hour EE; Change from Baseline in Total Calorie Intake at Lunch; Change from Baseline in Total Calorie Intake at Dinner; Change from Baseline in Fasting Appetite Visual Analog Score (VAS)